Clinical Trials Logo

Idiopathic Pulmonary Fibrosis clinical trials

View clinical trials related to Idiopathic Pulmonary Fibrosis.

Filter by:

NCT ID: NCT02803580 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

Start date: November 2015
Phase: N/A
Study type: Observational

The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation.

NCT ID: NCT02802345 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Start date: July 2016
Phase: Phase 3
Study type: Interventional

Efficacy will be assessed by the change from baseline in St George's Respiratory Questionnaire (SGRQ) total score at week 12 and at week 24; by the change from baseline in dyspnea using the University of California San Diego Shortness of Breath Questionnaire (UCSC SOBQ) at week 12 and at week 24; whereas safety will be assessed by the percentage of patients with on-treatment Serious Adverse Events (SAE) from baseline to week 24.

NCT ID: NCT02788474 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Start date: June 2016
Phase: Phase 4
Study type: Interventional

Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.

NCT ID: NCT02772549 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay

Start date: March 2016
Phase: N/A
Study type: Observational [Patient Registry]

Patients with newly diagnosed IPF are investigated for the diagnostic delay before a diagnosis of IPF is made.

NCT ID: NCT02759120 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (IPF)

CleanUp-IPF
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of standard care, versus standard of care plus antimicrobial therapy (co-trimoxazole or doxycycline), on clinical outcomes in patients diagnosed with idiopathic pulmonary fibrosis (IPF).

NCT ID: NCT02758808 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis Foundation Patient Registry

PFFR
Start date: March 2016
Phase: N/A
Study type: Observational [Patient Registry]

The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US. The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of well-characterized patients with interstitial lung disease (ILD) for participation in retrospective and prospective research

NCT ID: NCT02755441 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Early Diagnosis of Pulmonary Fibrosis - Use of Biomarkers in Idiopathic Pulmonary Fibrosis

Start date: April 2016
Phase: N/A
Study type: Observational

All incident cases of idiopathic pulmonary fibrosis (IPF) in Denmark will be offered inclusion during a 2 year period and followed up for at least 1 year with measurements of serum biomarkers and measurements of disease progression.

NCT ID: NCT02745184 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis

Start date: April 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive damage of lung structure and decline in lung function.This study intends to carry out an open, single-center, non-randomized, self control phase I clinical trial. During the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. Cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy after lavage. After twelve-month observation, the investigators will evaluate the safety and efficacy of the treatment by measuring the key clinical indicators.

NCT ID: NCT02739165 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Start date: May 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of the intravenous drip infusion of ART-123 in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) in a multicenter, double-blind, randomized, placebo-controlled, parallel group comparison study, and to confirm its superiority over placebo with survival rate on Day 90 as the primary endpoint.

NCT ID: NCT02738801 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690

Start date: March 2016
Phase: Phase 2
Study type: Interventional

A multicenter randomized, double-blind, parallel group, placebo-controlled, exploratory phase IIa study in subjects with Idiopathic Pulmonary Fibrosis (IPF) to evaluate safety, tolerability, PK and PD of GLPG1690. Male and female subjects aged 40 years or older will be screened to determine eligibility. The screening period will be up to 4 weeks. At baseline, eligible subjects will be randomized in a 3:1 ratio to GLPG1690 or matching placebo administered for 12 weeks. The subjects will visit the study center at screening, baseline, week 1, 2, 4, 8 and 12 and for a follow up visit 2 weeks after the last administration of study drug. Planned assessments: Adverse event reporting, clinical laboratory tests, vital signs, physical examination, 12-Lead-ECG, PK blood sampling, biomarker blood/BALF samples, Spirometry, St George's respiratory questionnaire, high-resolution computed tomography (HRCT).